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Introduction/Objective
Methodology
Treatment (n=10)
Chronic cough (CC), a cough that persists
longer than 8 weeks, impacts 11% of
- Progressive doses of capsaicin
• CCT, LCQ, UTC, VAS
Baseline Testing
through nebulizer
Americans. 15-20% do not respond to
- Coached to suppress cough
standard medical treatment and are
- Record urge to cough (UTC), difficulty
Treatment
diagnosed with refractory chronic cough
• Exp = 12 doses progressive capsaicin + 2 saline of suppression (DoS), and level of
(2x/wk, 6-12 sessions)
discomfort (LoD)
• Placebo = 12 exposures to saline
(RCC). Most of these patients suffer from
RCC due to hypersensitivity of airway
Placebo (n=8)
sensory nerves. The objective of this
Post test 1 (1 wk post)
Saline
through nebulizer
• CCT, LCQ, UTC, VAS
- No coaching
study is to assess validity of a new
- Did not record UTC, DoS, LoD
Outcome Measures
treatment for RCC called cough
CCT (cough challenge testing) - concentration of capsaicin that causes 5+ coughs (C5), without
desensitization treatment (CDT). CDT
trying to suppress; increased C5=reduced cough sensitivity
Research Design
involves exposing patients to aerosolized LCQ (Leicester Cough Questionnaire) - 19 questions about cough and QOL; max score=21; higher
score=less impact on QOL
Single blind RCT clinical trial
capsaicin, a known cough stimulant
UTC (urge-to-cough testing) - cough frequency and UTC from 0 (no UTC) to 10 (max UTC) after
found within chili peppers, in increasing exposure to several odors and vocal tasks. Reduction in both suggests reduced cough sensitivity
doses while actively suppressing cough. VAS (visual analog scale of cough severity) - 0-100; lower score=less severe

Results/Analysis
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A one-way analysis of covariance
(ANCOVA), with baseline scores as the
covariate, was used to evaluate the
group mean differences in LCQ scores
and cough sensitivity (i.e., logC5) at posttest 1. There was not a statistically
significant difference in LCQ scores
between the groups (p=.67 partial
h2=.012), but there was a statistically
significant difference between the
groups on logC5 (p=.01 partial eta2=.36)
with a large effect size. Assumptions for
a one-way ANCOVA were not met for
the VAS data so an independent samples
t-test comparing change in group means
was run. The difference in VAS scores
between the treatment and placebo
groups neared statistical significance
(p=.055, partial h2=.983) with a very
large effect size.
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Conclusion
The use of capsaicin to desensitize the
airway paired with behavioral cough
suppression therapy is a promising
treatment for those with chronic cough.
8 out of 10 patients in the treatment
group had clinically significant
improvement in their LCQ, with two
patients improving by 10+ points. There
is strong evidence that there was
greater improvement in the treatment
group's cough-reflex threshold
compared to the placebo group. This
means that the treatment group was
more desensitized at post-test 1 and
could withstand more capsaicin. The
mean VAS change reported in the
treatment group was four times greater
than that reported in the placebo
group, with large effect sizes. There is
strong evidence to show that the
placebo group improved as well. We are
unsure of this is due solely to placebo
effects or if it is a possible treatment
effect.
Future Directions
Plans for a multi-site study trial with the
University of Colorado, Emory University,
and the University of Utah are underway.

